Apogee Therapeutics Inc (APGE)
NasdaqGM · USD · Healthcare · Biotechnology
$135.07 (+0.00%) as of
Key statistics
- Market cap
- 10.22B
- Forward P/E
- -26.00
- EPS (TTM)
- -4.34
- 52-week range
- 35.39 – 135.09
- Beta
- 0.33
- Profit margin
- 0.00%
- Analyst target
- $134.62
About Apogee Therapeutics Inc
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Francisco, CA, United States
- Employees
- 261
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.